Warfarin and aspirin are similar in heart failure treatment

American Stroke Association late-breaking science - abstract LB12-4372

2012-02-06

(Press-News.org) In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

"Although there was a warfarin benefit for patients treated for four or more years, overall, warfarin and aspirin were similar," said Shunichi Homma, M.D., lead author of the study and the Margaret Milliken Hatch Professor of Medicine at Columbia University in New York.

In the 11-country Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, researchers followed 2,305 patients with heart failure and normal heart rhythm for up to six years (average 3.5 years). The patients were on average 61 years old, and the power of the heart's main pumping chamber, the left ventricle (left ventricular ejection fraction), was less than 35 percent (normal is 55 percent or higher).

Thirteen percent of the patients experienced a stroke or transient ischemic attack and were at heightened risk of recurrence. Patients with heart failure in general are at increased risk of death, blood clots and strokes.

Researchers randomly assigned patients to receive either 325 mg/day of aspirin or warfarin doses calibrated to a pre-specified level of blood thinning. Warfarin therapy requires frequent blood testing to monitor its dosage in order to achieve the desired level of blood thinning. In order to avoid bias, all patients had blood drawn on the same schedule and their pills adjusted so neither the patients nor their treating physicians knew which regimen they were taking.

Death, ischemic stroke (caused by blockage of an artery feeding the brain) or intracerebral hemorrhage (bleeding inside the brain), which combined were the study's primary endpoint, occurred at a rate of 7.47 percent for patients assigned to warfarin and 7.93 percent for patients assigned to aspirin. The difference was not statistically significant.

However, "in the group of patients followed for more than three years, those on warfarin did better in comparison to the aspirin patients," Homma said. Over the entire study period, patients receiving warfarin were just over half as likely to develop a stroke, a component of primary endpoint, as those taking aspirin. The rates of stroke were low with annual rates of 0.72 percent in patients assigned to warfarin and 1.36 percent for those on aspirin.

Researchers evaluated the safety of the anti-clotting medications by monitoring major bleeding events other than intracerebral hemorrhage (which was a component of the primary endpoint). Each year, major bleeds occurred in 1.8 percent of patients on warfarin and 0.9 percent of those on aspirin — a statistically significant difference.

"As expected, the overall bleeding rate was higher with warfarin," Homma said. "However, not all bleeds are equal, and the one that patients fear the most — bleeding within the brain (intracerebral hemorrhage) occurred rarely in both groups." It occurred in 0.12 percent per year in the warfarin group and 0.05 percent per year in the aspirin group.

"Given that there is no overall difference between the two treatments and that possible benefit of warfarin does not start until after 4 years of treatment, there is no compelling reason to use warfarin, especially considering the bleeding risk", Homma said. The investigators are analyzing whether certain subgroups of patients benefited more from each treatment.

### The study's co-author is John L.P. Thompson, Ph.D. and the WARCEF Investigators.

Author disclosures are on the abstract.

The National Institutes of Health/National Institute of Neurological Disorders and Stroke funded the study.

Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

NR12-1023 (ISC 2012/Homma)

(Note: Actual presentation is 12:48 p.m., Friday, Feb. 3, 2012)

Additional resources: All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at http://newsroom.heart.org/pr/aha/_prv-clopidogrel-with-aspirin-doesn-228204.aspx General ISC video and ISC photos available at http://www.newsroom.heart.org/ISC12-Video or http://www.newsroom.heart.org/ISC12-Photos. Follow news from ASA International Stroke Conference 2012 via Twitter: http://twitter.com/#!/heartnews. Follow #ASANews12.

ELSE PRESS RELEASES FROM THIS DATE:

Scientists chart high-precision map of Milky Way's magnetic fields

2012-02-06

Scientists at the Naval Research Laboratory (NRL) are part of an international team that has pooled their radio observations into a database, producing the highest precision map to date of the magnetic field within our own Milky Way galaxy. The team, led by the Max Planck Institute for Astrophysics (MPA), used the database they created and were able to apply information theory techniques to produce the map, explains NRL's Dr. Tracy Clarke, a member of the research team. "The key to applying these new techniques is that this project brings together over 30 researchers ...

A new study shows how to boost the power of pain relief, without drugs

2012-02-06

Placebos reduce pain by creating an expectation of relief. Distraction—say, doing a puzzle—relieves it by keeping the brain busy. But do they use the same brain processes? Neuromaging suggests they do. When applying a placebo, scientists see activity in the dorsolateral prefrontal cortex. That's the part of the brain that controls high-level cognitive functions like working memory and attention—which is what you use to do that distracting puzzle. Now a new study challenges the theory that the placebo effect is a high-level cognitive function. The authors—Jason T. Buhle, ...

Schooling protects fleeing children from disease

2012-02-06

Refugee children have scant access to medical care and are particularly vulnerable to disease. Fresh research results from the University of Copenhagen show that just a few hours of schooling a week may have a pronounced positive impact on their health not only in childhood but later in life when they achieve adulthood. "There is an unambiguous link between health and schooling among refugee groups as they flee," says external Associate Professor Tania Dræbel, PhD from the Department of Public Health, University of Copenhagen, where she works as an expert in health among ...

The complex relationship between memory and silence

2012-02-06

People who suffer a traumatic experience often don't talk about it, and many forget it over time. But not talking about something doesn't always mean you'll forget it; if you try to force yourself not to think about white bears, soon you'll be imagining polar bears doing the polka. A group of psychological scientists explore the relationship between silence and memories in a new paper published in Perspectives on Psychological Science, a journal of the Association for Psychological Science. "There's this idea, with silence, that if we don't talk about something, it starts ...

UC San Diego Moores Cancer Center offers new hope for deadly brain tumor

2012-02-06

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients. The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure. The TTF procedure uses alternating electrical fields to disrupt the ...

Largest Bin Database Service Released

2012-02-06

BinDataSet, an BIN database service provider, has released the largest BIN database on the Internet. The database contains over 350,000 records. What is BIN? BIN stands for Bank Identification Numbers. It is a database that contains credit and debit card numbers. On top of that, the database also provides additional information such as Country, Brand, and Bank. Most BIN databases provide only card type and brand. BinDataSet ensures that more fields are available for higher accuracy. Why is there a need for BIN databases? The Internet is growing at an amazing ...

New device removes stroke-causing blood clots better than standard treatment

2012-02-06

An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented by UCLA Stroke Center director Dr. Jeffrey L. Saver at the American Stroke Association's 2012 international conference in New Orleans on Feb. 3. The SOLITAIRE Flow Restoration Device is among an entirely new generation of devices designed to remove blood clots from blocked brain arteries in patients experiencing stroke. It has a self-expanding, stent-like design and, once inserted into a clot using a thin catheter ...

Coughing and other respiratory symptoms improve within weeks of smoking cessation

2012-02-06

New Rochelle, NY -- If the proven long-term benefits of smoking cessation are not enough to motivate young adults to stop smoking, a new study shows that 18- to 24-year olds who stop smoking for at least two weeks report substantially fewer respiratory symptoms, especially coughing. The study findings are detailed in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available online. Karen Calabro, DrPH and Alexander Prokhorov, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, ...

The Motorsport Lab Teams Up with Kaspersky Lab to Create an Unforgettable Corporate Ferrari Driving Experience Program

2012-02-06

As you are planning to create a corporate sales incentive program, look no further than The Motorsport Lab's supercar media. According to President and Founder Ray Chang, the purpose of The Motorsport Lab is to create a fun, exciting and once in a lifetime, interactive corporate experience using high-end supercars like Ferrari, Aston Martin and Lamborghini as a media platform. "Our difference is that we utilize supercars as a fun, versatile media platform for businesses to communicate value. Supercars offer aesthetic beauty inside and out will command instant ...

Regular use of vitamin and mineral supplements could reduce the risk of colon cancer

2012-02-06

Ottawa, Ontario –Could the use of vitamin and mineral supplements in a regular diet help to reduce the risk of colon cancer and protect against carcinogens? A study published in the Canadian Journal of Physiology and Pharmacology (CJPP) found that rats given regular multivitamin and mineral supplements showed a significantly lower risk of developing colon cancer when they were exposed to carcinogens. "It has been unclear whether multivitamin supplementation to cancer patients is helpful, has no effect, or is even detrimental during therapy," commented Dr. Grant Pierce, ...

Warfarin and aspirin are similar in heart failure treatment

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: